General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Negotiations were not pursued
Manufacturer:
Bayer Inc.
Indication:
Pulmonary Arterial Hypertension (WHO group 1)
Last updated January 31, 2017
Status:
Negotiations were not pursued
Manufacturer:
Amgen Canada Inc.
Indication:
Prevention of skeletal-related events due to bone metastases from breast cancer
Last updated January 31, 2017
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
Metastatic Renal Cell Carcinoma
Last updated January 20, 2017
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
Non-small Cell Lung Cancer
Last updated January 20, 2017
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
Metastatic Melanoma
Last updated January 20, 2017
Status:
Negotiations were not pursued
Manufacturer:
Gilead Sciences Canada Inc.
Indication:
Follicular lymphoma, Relapsed or refractory
Last updated January 13, 2017
Status:
Concluded with an LOI
Manufacturer:
Amgen Canada Inc.
Indication:
Acute Lymphoblastic Leukemia (ALL)
Last updated January 9, 2017
Status:
Negotiations were not pursued
Manufacturer:
Janssen Inc.
Indication:
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Last updated December 23, 2016
Status:
Negotiations were not pursued
Manufacturer:
Janssen Inc.
Indication:
Multiple Myeloma
Last updated December 23, 2016
Status:
Negotiations were not pursued
Manufacturer:
AbbVie Corporation
Indication:
Hidradenitis Suppurativa
Last updated December 22, 2016